Oncolytics signs supply pact with Coherus for pelareorep and toripalimab
Oncolytics Biotech and Coherus Oncology entered a clinical supply agreement to evaluate pelareorep in combination with LOQTORZI. This partnership aims to assess the combination in second-line squamous cell anal carcinoma patients with no currently approved therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed